[{"orgOrder":0,"company":"Alpheus Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"||Protoporphyrinogen oxidase; Delta-aminolevulinic acid dehydratase","graph1":"Oncology","graph2":"Phase I","graph3":"Alpheus Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alpheus Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpheus Medical \/ Inapplicable"},{"orgOrder":0,"company":"Alpheus Medical","sponsor":"Alpheus Medical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"||DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Alpheus Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alpheus Medical \/ Alpheus Medical","highestDevelopmentStatusID":"6","companyTruncated":"Alpheus Medical \/ Alpheus Medical"},{"orgOrder":0,"company":"Alpheus Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alpheus Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpheus Medical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alpheus Medical \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Alpheus Medical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Low-Intensity Diffuse Ultrasound with the sensitizing agent, oral 5-aminolevulinic acid (5-ALA) is being investigated in patients with recurrent or refractory high-grade gliomas.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 24, 2024

                          Lead Product(s) : Aminolevulinic Acid HCl,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 30, 2024

                          Lead Product(s) : Aminolevulinic Acid HCl,CV01

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Universität Münster

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 05, 2022

                          Lead Product(s) : Aminolevulinic Acid HCl,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank